Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06432075
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-05-16
Brief Title:
Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer
Sponsor:
First Affiliated Hospital of Wenzhou Medical University
Organization:
First Affiliated Hospital of Wenzhou Medical University
Study Overview
Official Title:
Single Arm Clinical Prospective Study of Neoantigen Reactive T Cells NRTs in the Treatment of Chinese Patients With Advanced Gastric Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see the safety and efficient of neoantigen reactive T cells NRTs in the treatment of Chinese patients with advanced gastric cancer
Detailed Description:
The tumor-specific none-self immunogenic neoantigens encoded by either viral genes or somatic mutation genes possess the potential to induce specific anti-cancer immunity including cellular and humoral immune responses Today numerous clinical trials demonstrate that although these none-self antigens initiate the antigen-specific immunoglobulin G antibodies and cluster of differentiation 4CD4cluster of differentiation 8CD8T-cells response not all of them show a clinical benefit in the response rate progression-free survival or overall survivalPersonalized cell therapy maybe own a breakthrough in the treatment of those gastric cancer patients without standard optionsThe investigators center has successfully established a new method for preparing personalized neoantigen reactive T cellsNRTS for adoptive cell therapyACT Today the investigators will carry out a single arm clinical prospective study of NRTs for the treatment of Chinese patients with advanced gastric cancer Participants are assigned to receive 4 circles of cell therapy and IL-2 continuous intravenous infusionCIV will also be given for 5 consecutive days after each times cell infusion The safety and clinical response rateRR are evaluated Biomarkers and immunological markers are also monitored
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None